BRCA1 and ovarian cancer: In an international, multicenter, double-blind, randomized, placebo-controlled phase 3 trial (SOLO2 trial, NCT01874353), it was found that the median PFS assessed by the investigator in PSR ovarian cancer with germline BRCA1 or BRCA2 mutation (gBRCA) was significantly longer in the olaparib arm at 19.1 months, compared with 5.5 months in the placebo arm.